Zura Bio Advances Tibulizumab Strategy in Autoimmune Diseases

Zura Bio ( (ZURA) ) has shared an announcement.

On Feb. 11, 2026, Zura Bio released an updated corporate presentation outlining its strategy to advance tibulizumab, a bispecific antibody designed to inhibit both IL-17 and BAFF, as a novel treatment for complex autoimmune diseases. The company highlighted Phase 1 data showing potent target engagement and low immunogenicity, and positioned tibulizumab as a candidate to overcome efficacy limits seen with single-pathway drugs.

The presentation detailed an initial clinical focus on hidradenitis suppurativa and systemic sclerosis, targeting both skin and lung manifestations in the latter, and framed tibulizumab as a potential best-in-class or first-in-disease therapy in these indications. Management also emphasized Zura Bio’s funding runway through 2027, with topline data from Phase 2 studies in hidradenitis suppurativa and systemic sclerosis expected in the fourth quarter of 2026 and the first half of 2027, milestones that could materially influence its clinical and commercial trajectory.

The most recent analyst rating on (ZURA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.

Spark’s Take on ZURA Stock

According to Spark, TipRanks’ AI Analyst, ZURA is a Neutral.

Score is held back primarily by weak financial performance (pre-revenue, widening losses, and significant cash burn), partially offset by strong technical momentum and positive corporate updates supporting clinical progress and a stated funding runway through 2027. Valuation signals remain constrained by unprofitability and lack of dividend data.

To see Spark’s full report on ZURA stock, click here.

More about Zura Bio

Zura Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies for complex immune and autoimmune disorders. Its lead asset, tibulizumab, is a first-in-class bispecific antibody targeting both IL-17 and BAFF pathways, initially aimed at treating hidradenitis suppurativa and systemic sclerosis, where both B-cell and T-cell driven pathobiology are implicated.

The company is listed on Nasdaq under the ticker ZURA and reported approximately $139 million in cash as of Sept. 30, 2025, which it expects will fund planned operations through 2027. Zura Bio had about 101 million shares outstanding on an as-converted basis as of Dec. 31, 2025, excluding potential dilution from stock options and unvested RSUs, and is advancing Phase 2 studies designed to deliver key clinical data over the next two years.

Average Trading Volume: 641,639

Technical Sentiment Signal: Buy

Current Market Cap: $390.8M

For detailed information about ZURA stock, go to TipRanks’ Stock Analysis page.